Remedium Capital Partners, LLC VC / PE / Holdco

CIK: 0002104501 · Show all filings

Period: Q4 2025

Filing Date: Feb 12, 2026

Total Value ($000): $170 (100.0% shares, 0.0% debt)

Holdings (6)

SYRE Spyre Therapeutics Inc 28.0%

Value ($000) $48 Shares 1,456,231 Est. Cost $26.13 Unrealized 0.0%

ORKA Oruka Therapeutics Inc 27.6%

Value ($000) $47 Shares 1,552,414 Est. Cost $27.86 Unrealized 0.0%

APGE Apogee Therapeutics Inc 25.9%

Value ($000) $44 Shares 583,591 Est. Cost $62.99 Unrealized 0.0%

JBIO Jade Biosciences Inc 14.3%

Value ($000) $24 Shares 1,577,750 Est. Cost $11.73 Unrealized 0.0%

— Crescent Biopharma Inc 2.5%

Value ($000) $4 Shares 361,250 Est. Cost $0.01 Unrealized —

GLTO Galecto Inc 1.6%

Value ($000) $3 Shares 120,473 Est. Cost $17.38 Unrealized 0.0%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
SYRE	Spyre Therapeutics Inc	1,456,231	$48	28.0%	$26.13	0.0%	COM	00773J202
ORKA	Oruka Therapeutics Inc	1,552,414	$47	27.6%	$27.86	0.0%	COM	687604108
APGE	Apogee Therapeutics Inc	583,591	$44	25.9%	$62.99	0.0%	COM	03770N101
JBIO	Jade Biosciences Inc	1,577,750	$24	14.3%	$11.73	0.0%	COM	008064206
—	Crescent Biopharma Inc	361,250	$4	2.5%	$0.01	—	COM	38000Q201
GLTO	Galecto Inc	120,473	$3	1.6%	$17.38	0.0%	COM	36322Q206